PARP inhibitors: A review of the pharmacology, pharmacokinetics, and pharmacogenetics

PARP inhibitors have emerged as a promising class of anticancer agents approved for the treatment of ovarian, breast, prostate, and pancreatic cancer. These inhibitors target PARP enzymes involved in DNA repair pathways and exhibit remarkable efficacy in cancers with genetic deficiencies in the homo...

Full description

Saved in:

Bibliographic Details
Published in:	Seminars in oncology Vol. 51; no. 1-2; p. 19
Main Authors:	Zeng, Yi, Arisa, Oluwatobi, Peer, Cody J, Fojo, Antonio, Figg, William D
Format:	Journal Article
Language:	English
Published:	United States 01.02.2024
Subjects:	Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Female Humans Neoplasms - drug therapy Neoplasms - genetics Ovarian Neoplasms - genetics Pharmacogenetics Poly(ADP-ribose) Polymerase Inhibitors - pharmacology Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use Pharmacogenetics DNA Repair PARP Inhibitors Oncology Pharmacology Pharmacokinetics Cancer
ISSN:	1532-8708, 1532-8708
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!